The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global allergy treatment market size reached US$ 19.69 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 28.78 Billion by 2027, exhibiting a growth rate (CAGR) of 6.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Allergy treatment is a preventive medical cure for abnormal reactions to allergens, such as pollens, molds, animal dander, latex, insects, food, and medications. They trigger the release of histamine by the immune system that causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes. They can also cause various allergic conditions, including hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic drugs and immunotherapy that can be administered through oral, inhalers, and intranasal dosage forms. These treatment methods help reduce sensitivity and inflammation, decrease symptoms, and improve the quality of the patient’s life.
The increasing prevalence of various allergies across the globe is one of the primary factors driving the market growth. In line with this, favorable initiatives by governments and non-governmental organizations (NGOs) to sensitize the masses about the adversities of allergies and their appropriate treatment options are favoring the market growth. Furthermore, increasing demand for over-the-counter (OTC) drugs, coupled with a growing inclination toward self-medication among consumers, is acting as another growth-inducing factor. Additionally, the integration of artificial intelligence (AI), natural language processing (NLP), and machine learning (ML) for diagnosing allergic diseases, predicting patient outcomes for targeted interventions, analyzing immunological data, and improving care delivery is providing an impetus to market growth. Apart from this, the increasing demand for subcutaneous allergen-specific immunotherapy (SCIT) due to its effectiveness, safety, and ability to alter the immune system and provide systemic relief is creating a positive outlook for the market. Other factors, including significant healthcare expenditures, increasing geriatric population, extensive research and development (R&D) activities towards novel treatments, and rising incidences of asthma, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global allergy treatment market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment, dosage form and distribution channel.
Breakup by Type:
Breakup by Treatment:
Breakup by Dosage Form:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Treatment, Dosage Form, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., ALK-Abelló A/S, Allergopharma (Dermapharm AG), Allergy Therapeutics, Almirall S.A, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, HAL Allergy Group (Droege International Group), Leti Pharma, Nicox S.A., Sanofi S.A. and Stallergenes Greer.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at